Inato, a Paris, France-based platform for biopharmaceutical companies to increase the pool of available patients engaged in clinical trials, raised $14m in Series A funding.
The round was led by Obvious Ventures and Cathay Innovation, with participation from previous investors Serena and Fly Ventures. As a part of the financing, Nan Li, managing director at Obvious Ventures, has joined Inato’s board of directors.
The company intends to use the funds to expand its predictive capabilities to match the right sites with the right studies and develop a comprehensive network of clinicians worldwide.
Led by CEO Kourosh Davarpanah, William Pambrun, Pr. Philippe Ravaud, Chief Medical Officer Dr. Jean-David Zeitoun, and CSO Liz Beatty, Inato provides a platform that increases the pool of available patients engaged in clinical trials by unlocking research site potential. The platform matches the best sites for any given study and ensures that site partners in the network are delivering trials.
To date, the company has helped biopharmaceutical companies and clinicians across more than 2,000 research sites and over 50 global trials. In addition, more than 3,500 doctors across 75 countries have used it to offer treatments to their patients.
Inato also has offices in New York and London.